planes de pago
¿Quieres analizar varias empresas a la vez? Los planes de pago te permiten comparar hasta 5 acciones lado a lado.
Regístrate
S
014950
vs
K
KOSPI 200
En los últimos 12 meses, Samik Pharm Co Ltd ha quedado por detrás de KOSPI 200, con una rentabilidad de -46% frente a un crecimiento de +46% de KOSPI 200.
Rendimiento de las acciones
014950 vs KOSPI 200
Diferencia de rendimiento
014950 vs KOSPI 200
Rendimiento por año
014950 vs KOSPI 200
Compara la rentabilidad de la acción con su índice de referencia y sus competidores. Obtén información sobre su rendimiento relativo a lo largo del tiempo.
Rendimiento de los competidores
Samik Pharm Co Ltd vs pares
Samik Pharm Co Ltd
Vista general
Samik Pharm Co., Ltd. engages in the manufacture and sale of pharmaceuticals. The company is headquartered in Incheon, Incheon. The company went IPO on 2025-10-27. The firm is mainly engaged in the manufacture of drugs such as circulatory machinery treatments such as Cesar Plus tablets and Eravix tablets, diabetes treatments such as Griffin tablets and Gluemser tablets, digestive machinery treatments such as Samik Pharmotidine tablets and Rebacode tablets, and antipyretic anti-inflammatory drugs such as Tamitrasemi tablets and Seklfen tablets. In addition, the Company is also engaged in the manufacturing of drugs such as treating acute or recurrent vaginal candidiasis, treating children with motion sickness, and treating alopecia. The firm sells its products in domestic and overseas markets.